(RTTNews) - Moderna Inc. (MRNA) said that the first participants have been dosed in the Phase 1 study of mRNA-1283, the company's next generation COVID-19 vaccine candidate. The vaccine candidate is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers.
According to the company, the Phase 1 dose-ranging study will assess the safety and immunogenicity of mRNA-1283. The study will evaluate three dose levels, 10 µg, 30 µg, and 100 µg, of the mRNA-1283 vaccine candidate given to healthy adults as a 2-dose series, 28 days apart, and one dose level, 100 µg, of mRNA-1283 given to healthy adults in a single dose. These will be compared with a 2-dose series of 100 µg of mRNA-1273, the currently authorized dose level.
The company noted that mRNA-1283 is intended to be evaluated in futures studies for use as a booster dose for previously vaccinated or seropositive as well as in a primary series for seronegative individuals.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
